It is designed to selectively target RET alterations and block the abnormal signalling pathways that drive tumour growth.
Eli Lilly has officially launched its new cancer drug, Tanstrive, in the Indian market. This innovative medication is priced at Rs 2.15 lakh per box and is designed to selectively target RET alterations. By blocking abnormal signalling pathways, Tanstrive aims to effectively…
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.